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Whilst not yet published in full, the PALACE 2 and 3 studies have been presented in abstract form. 6, 7 Both were similar in design to PALACE 1, with patients in PALACE 2 allowed to continue DMARDs at stable doses. In PALACE 3, patients were required to have at least one psoriatic lesion ≥2 cm in diameter at baseline. In both studies, the ACR20 primary outcome measure was achieved at week 16 and maintained over 52 weeks' follow-up. Secondary outcome measures, such as PASI scores, also improved and adverse events were similar to those reported for PALACE 1. The FDA approval notes that weight loss occurred in a small number of patients in the PALACE studies and recommends that patients should have their weight monitored regularly; 8 they also noted that apremilast treatment was associated with an increase in reports of depression compared with placebo.
The FDA approval of apremilast in PsA is to be welcomed for a number of reasons. Firstly, therapeutic options for PsA are limited with no synthetic DMARD approved for use and only anti-TNF therapies and ustek inumab approved biologic drugs. Approximately 70% of anti-TNF-treated patients achieve an ACR20 response, 9 which means that ~30% do not, and for many the treatment responses are not adequate enough for the patient to be considered as in a minimal disease activity state. Additional options are, therefore, required. Secondly, the PALACE studies suggest that disease features such as enthesitis might also respond to apremilast. With little or no data on res ponse of enthesitis to DMARDs such as metho trexate, this possible benefit of apremilast is potentially of importance when selecting appropriate therapy. Thirdly, the sustained response associated with a low frequency of serious adverse events is important when compared to a drug like methotrexate, which can be difficult to persuade patients to take because of concerns, perhaps exaggerated, regarding adverse effects and its listing as a 'cancer drug' .
Many questions remain that will require fur ther study. These questions include whether apremilast can or should be used in combination with other synthetic or biologic DMARDs. Further analysis of the PALACE studies might shed some light on this matter, but a specific study of apremilast ver sus a competitor versus a combination of the two may well be required. The question of a specific comparison with methotrexate is going to be of especial interest, for might it not only assist in answering once and for all whether or not methotrexate is effective, but also it will position apremilast along the treatment pathway and perhaps indicate that, in certain patients, a combination of apremilast with metho trexate could be considered. Whilst welcoming the arrival of apremilast, the rheumatology community eagerly awaits the answers to these questions. Fractured bones normally heal spontan eously but, to ensure that they heal in a correct position, they are often fixed with metal nails, screws or plates. These implants are often removed by a new operation when the fracture is healed. In an article published in Nature Communications, Perrone et al. 1 presented for the first time a solid, machin able material made of silk protein. They manufactured self-tapping screws that could be inserted in bone and that degrade slowly over time; the ability to degrade would elimi nate the need for surgical removal of the implant. The material seemed to soften and swell with hydration, which is an obvious problem. The study authors implanted silk screws in intact rat femora, and measured the force needed to pull them out after 4 and 8 weeks. This force reflects the strength of the new bone that has formed within the screw threads. For the silk screws, it amounted to less than one-third of that reported for similar-sized metal screws in rat tibiae, 2 but this finding might be explained by differences in study design. Histological analysis of the implant site showed degradation of the implant surface and giant cells, possibly indicating a foreign body reaction, together with bone formation. Obviously, more work is needed before it can be concluded for what purpose this material might become useful in bone surgery.
Removal of fracture fixation implants after healing is a surgical operation not with out risk. Avoiding such surgery has been a main rationale for the development of degradable implants. Degradable implants made of different polylactic-glycolic acids have been available for decades, but gained limited popularity. The main improvement with the new silk material would be that it can be machined to form more precisely shaped devices, and sterilized by autoclaving. Further more, the degradation of po lylacticglycolic acid implants is associated with local inflammation and sometimes sinus formation in the bone that can be detrimental. 3, 4 Perrone et al. 1 hope that this issue will be less of a problem with silk.
Removal of internal fracture fixation devices can be commonplace, but it is unclear how often it is necessary. Any sur gery should have a clear motivation, but for implant removal the underlying reasoning behind the procedure is often simply that the implant is in there and so must be taken out. If implant retainment is not associated with any risk or discomfort, this reason for removal is irrational. Such irrationality is not uncommon: benign cavities in bone are often treated with unnecessary void fillers, as a result of some kind of ortho paedic 'horror vacui' . 5 Similarly, there might be an orthopaedic 'xeno phobia' behind unnecessary removal of foreign materials. Interest ingly, implant retainment is not regarded as a problem in the context of total joint replacements (and who would like to have a degradable hip replacement?).
Perrone et al. 1 argue that metal implants need removal because of stress shielding, which relates to loss of mechanical loading of the bone adjacent to the implant as a result of its placement, and subsequent bone resorption in that area due to lack of mechanical stimulation. Stress shielding under metal plates has previously been thought to necessitate early removal of the plate or the use of less stiff materials. How ever, the bone changes observed under metal plates seem to be caused by surgical devascularization during the implantation procedure. 6 With less-traumatic surgery and plates designed to cause less disturbance of the vascular supply to the bone, the problems ascribed to stress shielding have largely disappeared. 6 Regardless of the design of fracture fixation devices, the bone normally seems to be sufficiently loaded to maintain itself. 7 When implants really need to be removed, it is almost exclusively because they protrude out of the bone and cause dis comfort, for example at the tibial tuberosity when kneeling. Plates can also interfere with tendons gliding over them, causing local inflammation, and such complications might neces sitate implant removal. How ever, if these implants were instead de gradable, the inflammation associated with degradation might even cause worse local problems. For instance, the new silk ma terial is degraded enzymatically, and histo logical analysis demonstrated formation of fragments and particles at the screw sur face. 1 Phago cytosable particles tend to cause inflam mation, even if the material is biocompatible in bulk form. This pro cess can reduce formation and increase resorption of bone, which might explain the low pull-out force of the silk screws. As metal implants cause minor issues, it is imperative that a solution to those issues does not itself cause further problems.
Implant removal is surprisingly common. In Sweden, 37,000 adult patients received metal fracture fixation implants in 2011, and 13,000 underwent implant removal. The number of adults undergoing fracture sur gery in Sweden increased from 2005 to 2011 by 20%, but removals increased by 35%. 8 The highest rate of removal (70%) was reported for ankle and foot implants. Liga mentous healing and adaptation after an ankle fracture can take years, and symptoms can be erroneously ascribed to remaining, palpable implants. Removal rates might also be influenced by economic incitements. Still, in many cases, the reason can just be tradition. In children, metal implants are routinely removed, although it can often be unnecessary. 9, 10 In many cases, a retained implant would be hidden inside the lar ger bone eventually formed by growth. An argument put forward for implant removal in children is that an implant left behind from young age might interfere with fracture surgery later in life. Children are exposed to surgery just to reduce possible technical problems in the unlikely event that the same bone needs surgery in adulthood! Implants for fracture fixation sometimes do need to be removed, and a per fect implant therefore would maintain strength until the fracture is healed, and then disappear quickly without substantial local inflammation. Unfortunately, an implant that is required to remain intact for months would probably take years to disappear. Situations do, however, exist (for example, in the treatment of ankle fractures) in which screws are expected to hold only for the short time needed for soft tissue healing and then loosen their grip to enable small motions. Silk screws might become a practical possibility in this scenario. Crucially, this new material 1 might enable applications we have not yet thought of and future experimentation is warranted. How ever, degradation of implants might sometimes cause problems related to inflammation, metal implants work well, and unnecessary removal of metal implants might be a greater issue than implant retainment.
